Twist Bioscience Corp TWST
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TWST is a good fit for your portfolio.
News
-
Twist Bioscience to Report Fiscal 2024 Second Quarter Financial Results on Thursday, May 2, 2024
-
Twist Bioscience Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations
-
Twist Bioscience Launches IVDR-compliant Precision Dx Products for Whole Exome Sequencing
-
Twist Bioscience to Present at Upcoming Investor Conferences
-
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Twist Bioscience and Element Biosciences Collaborate on Exome Sequencing Solutions for AVITI System
-
Twist Bioscience Launches cfDNA Library Preparation Kit for Liquid Biopsy Applications
-
Twist Bioscience Unveils Differentiated Ultra High-Throughput Library Preparation Solution at AGBT
Trading Information
- Previous Close Price
- $30.75
- Day Range
- $29.76–31.29
- 52-Week Range
- $11.46–43.21
- Bid/Ask
- $27.49 / $31.08
- Market Cap
- $1.80 Bil
- Volume/Avg
- 1.2 Mil / 879,831
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.70
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.32%
Company Profile
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Growth
- Total Number of Employees
- 919
- Website
- https://www.twistbioscience.com
Comparables
Valuation
|
Metric
|
TWST
|
PACB
|
TXG
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.01 | 0.53 | 4.32 |
Price/Sales | 6.70 | 1.75 | 5.09 |
Price/Cash Flow | — | — | — |
Price/Earnings
TWST
PACB
TXG
Financial Strength
|
Metric
|
TWST
|
PACB
|
TXG
|
|---|---|---|---|
Quick Ratio | 5.31 | 7.03 | 3.96 |
Current Ratio | 5.98 | 7.81 | 4.69 |
Interest Coverage | −55,011.75 | −21.18 | −8,049.58 |
Quick Ratio
TWST
PACB
TXG
Profitability
|
Metric
|
TWST
|
PACB
|
TXG
|
|---|---|---|---|
Return on Assets (Normalized) | −19.59% | −15.38% | −11.53% |
Return on Equity (Normalized) | −24.08% | −41.87% | −14.67% |
Return on Invested Capital (Normalized) | −22.74% | −16.60% | −14.55% |
Return on Assets
TWST
PACB
TXG
Diagnostics & Research Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Gbyzjczny | Pxqrq | $209.3 Bil | |
DHR
| Danaher Corp | Qsvvlvrrn | Jfwsnfd | $182.1 Bil | |
IQV
| IQVIA Holdings Inc | Lhrytbrdv | Jmqzbp | $43.4 Bil | |
IDXX
| IDEXX Laboratories Inc | Mtmhgmdhy | Rnmmrv | $41.0 Bil | |
A
| Agilent Technologies Inc | Fmwxgyhlqc | Wsmb | $40.3 Bil | |
MTD
| Mettler-Toledo International Inc | Pcqjqsdpv | Kdjxlf | $26.4 Bil | |
ICLR
| Icon PLC | Xkfccpldx | Zkbnm | $24.8 Bil | |
ILMN
| Illumina Inc | Qjbrjqyd | Tkbpbcq | $19.3 Bil | |
WAT
| Waters Corp | Ssssjnhx | Rvq | $18.3 Bil | |
LH
| Laboratory Corp of America Holdings | Kvwxzvyts | Qbwpmw | $17.5 Bil |